SAN DIEGO, Nov. 07, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 and provided an update on its corporate activities and product pipeline. "The last several months represent a truly transformative period for Cidara. Our partnership with Mundipharma validated the significant commercial potential of rezafungin and provides financial and other resources that enable us to continue…

SAN DIEGO, Nov. 05, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14 in New York City for institutional investors, sell-side analysts, and business development professionals. The meeting will feature presentations from Key Opinion Leaders, Neil J. Clancy, M.D. (University of Pittsburgh), Kieren Marr, M.D. (Johns Hopkins University…

SAN DIEGO, Oct. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which takes place October 2-6, 2019, in Washington, D.C., and four posters, including a late-breaking poster, at the 9th Trends in Medical Mycology (TIMM), which takes place October 11-14, 2019, in Nice, France. The presentations at IDWeek will…

SAN DIEGO, Sept. 16, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala, chief operating officer, and James Levine, chief financial officer of Cidara are scheduled to participate in 1x1 meetings with investors at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, which takes place on September 23, 2019, and that Jeffrey Stein, Ph.D., president and chief executive officer of…

Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan, which will be retained by Cidara Cidara to receive upfront payment of $30 million and equity investment of $9 million, co-development funding, development milestones and tiered royalty stream Total transaction value could exceed $568 million Cidara to…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore. "Cidara's presentations at this important global conference highlight our commitment to addressing an unmet medical need for better and more effective approaches…

SAN DIEGO, Aug. 08, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial results for the three months ended June 30, 2019 and provided an update on its corporate activities and product pipeline. "We have made important advances in both our rezafungin program to treat and prevent fungal disease as well as our Cloudbreak® immunotherapy program for the treatment and prevention of influenza," said Jeffrey Stein,…

SAN DIEGO, Aug. 07, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 10:20 a.m. EDT (7:20 a.m. PDT) in New York City. A live audio webcast and replay of the presentation will be available in the Investors section…

Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Global Phase 3 ReSTORE trial ongoing Company to host conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, July 29, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline results from Part B of the global…

Company secures two oral and four poster presentations Presentations include new data highlighting the antiviral effect and immune system engagement of CB-012 for the prevention and treatment of flu SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of rezafungin, the company's Phase 3 antifungal, and CB-012, its Cloudbreak® antiviral Fc-conjugate (AVC) candidate for influenza, will be presented at the American…